So far, serious side effects havent been common, but heres what an early phase 2 study has shown: Pancreatitis: Happened in about 0.4% of people in the study Gallbladder problems: Reported in about 1.1% of participants Heart rhythm changes: Seen more often with retatrutide, about 6% compared to 3% with placebo Liver enzyme changes: Around 1% of participants had increases, but overall liver health stayed stable These results suggest a low but real chance of serious issues such as pancreatitis, gallbladder problems, severe GI events, and allergic reactions
One app
If a compounded semaglutide vial freezes, it is no longer safe to use
Biosci Biotechnol Biochem
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
This phenomenon might be noticeable in the first few weeks of treatment or after dose increases, though this mechanism has not been specifically studied in GLP-1 clinical trials